#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sickle cell anaemia Restless legs syndrome Lymphangiosarcoma Pleural mesothelioma Spinal muscular atrophy Neuroendocrine tumour Palmoplantar pustulosis Pelizaeus-Merzbacher disease Duchenne muscular dystrophy gene carrier Deafness neurosensory Barth syndrome Encephalopathy neonatal Alexander disease Acute myeloid leukaemia Wiskott-Aldrich syndrome More trials…

    Learn about Rare Diseases

    Breast angiosarcoma – Basic Information Thrombotic thrombocytopenic purpura – Basic Information Lymphatic malformation – Diagnostics Ornithine transcarbamoylase deficiency – Life with Disease Langerhans’ cell histiocytosis – Trials in Disease Crigler-Najjar syndrome – Basic Information Piriformis syndrome Short-bowel syndrome – Basic Information Familial haemophagocytic lymphohistiocytosis – Diagnostics Adrenocortical carcinoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eribulin Oxitriptan Amitriptyline Hydrochloride Ribonucleic Acid K30 ALPROSTADIL Suxamethonium Chloride Elacestrant Dihydrochloride Prilocaine AP31969 SULFATE Tezacaftor LINAPRAZAN GLURATE Magnesium Oxide, Light Vemurafenib ZODASIRAN Lovotibeglogene Autotemcel Berubicin Hydrochloride Indocyanine Green ANOC-001 Cytarabine XYLOMETAZOLINE HYDROCHLORIDE More therapies…

    Learn about Your Condition

    Dermatitis atopic Acute hepatic failure Knee arthroplasty Ewing's sarcoma metastatic Sickle cell anaemia Circulatory collapse Urticaria cholinergic Perthes disease Meningioma malignant Post procedural infection Primary hyperaldosteronism Gastric cancer Oropharyngeal cancer recurrent Trigeminal neuralgia Asthma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie…

Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie

Ul. Jagiellonska Nr 78, Olsztyn, 10-357, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ramucirumab
    • Rilvegostomig
    Belgium France Germany Italy The Netherlands Poland +1

  • A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Pulmonary fibrosis
    Investigated Drugs:
    • ADMILPARANT
    Austria Belgium Czechia Denmark Finland France +9

  • A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • ADMILPARANT
    Austria Belgium Czechia Denmark Finland France +9

  • Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Zipalertinib
    • Carboplatin
    • Cisplatin
    Belgium France Germany Greece Italy The Netherlands +3

  • Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    Investigated Drugs:
    • Vinorelbine
    • Carboplatin
    • Cisplatin
    Belgium France Germany Hungary Italy The Netherlands +3

  • Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cobolimab
    • Dostarlimab
    • Docetaxel
    Belgium Finland France Germany Greece Italy +5

  • Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Croatia Greece Lithuania Poland Romania Spain

  • Study Comparing Alectinib and Crizotinib for Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Anaplastic lymphoma kinase gene mutation
    Investigated Drugs:
    • Alectinib
    • Crizotinib
    • Alectinib Hydrochloride
    Italy Poland Portugal Spain

  • Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Savolitinib
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria France Germany Greece +3

  • Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Durvalumab
    Austria Belgium France Germany Hungary Italy +3
Previous Page
1 2 3 4 5 6 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!